Daniel W. Muehl - 01 Sep 2021 Form 4 Insider Report for Clovis Oncology, Inc.

Role: Executive Vice President and Chief Financial Officer
Signature: /s/ Daniel Muehl
Issuer symbol: N/A
Transactions as of: 01 Sep 2021
Net transactions value: -$1,218
Form type: 4
Filing time: 03 Sep 2021, 16:16:13 UTC
Previous filing: 03 Aug 2021
Next filing: 03 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLVS	Common Stock	Options Exercise		+563	+0.92%		61,613	01 Sep 2021	Direct	F1
transaction	CLVS	Common Stock	Sale	$1,218	-249	-0.4%	$4.89	61,364	02 Sep 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLVS	Restricted Stock Units	Options Exercise	$0	-563	-33%	$0.000000	1,125	01 Sep 2021	Common Stock	563		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2	Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3	On March 1, 2018, the reporting person was granted 9,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Executive Vice President and Chief Financial Officer